Restoration of natural killer cell cytotoxicity by VEGFR-3 inhibition in myelogenous leukemia

Cancer Letters

Volumn 354, Issue 2, 2014, Pages 281-289

  Lee, Ji Yoon ^a   Park, Sohye ^a   Min, Woo Sung ^a   Kim, Hee Je ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Interferon ; Leukemia; Natural killer cell; VEGFR 3

Indexed keywords

GAMMA INTERFERON; MAZ 51; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VASCULOTROPIN C; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 3; 3-(4-DIMETHYLAMINO-NAPHTHALEN-1-YLMETHYLENE)-1,3-DIHYDRO-INDOL-2-ONE; INDOLE DERIVATIVE; NAPHTHALENE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC GENE THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INFILTRATION; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENE SILENCING; IFN GAMMA GENE; LYMPHANGIOGENESIS; MOUSE; MYELOID LEUKEMIA; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; PROTEIN EXPRESSION; RECEPTOR BLOCKING; TUMOR MICROENVIRONMENT; VEGF C GENE; VEGFR 3 GENE; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CYTOTOXICITY; DISEASE MODEL; GENETIC TRANSFECTION; GENETICS; IMMUNOLOGY; LEUKEMIA, MYELOID, ACUTE; METABOLISM; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; INDOLES; INTERFERON-GAMMA; KILLER CELLS, NATURAL; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, INBRED C57BL; NAPHTHALENES; RNA, SMALL INTERFERING; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 84907975873     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.08.027     Document Type: Article

References (38)

1. Ferrara F., Schiffer C.A. Acute myeloid leukaemia in adults. Lancet 2013, 381:484-495.
2. Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science 2013, 342:1432-1433.
3. Schreiber R.D., Old L.J., Smyth M.J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011, 331:1565-1570.
4. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol 2006, 6:295-307.
5. Adams R.H., Alitalo K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat. Rev. Mol. Cell Biol 2007, 8:464-478.
6. Fielder W., Graeven U., Ergun S., Verago S., Kilic N., Stockschlader M., et al. Expression of FLT4 and its ligand VEGF-C in acute myeloid leukemia. Leukemia 1997, 11:1234-1237.
7. Smith N.R., Baker D., James N.H., Ratcliffe K., Jenkins M., Ashton S.E., et al. Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers. Clin. Cancer Res 2010, 16:3548-3561.
8. Krebs R., Tikkanen J.M., Ropponen J.O., Jeltsch M., Jokinen J.J., Yla-Herttuala S., et al. Critical role of VEGF-C/VEGFR-3 signaling in innate and adaptive immune responses in experimental obliterative bronchiolitis. Am. J. Pathol 2012, 181:1607-1620.
9. Dias S., Choy M., Alitalo K., Rafii S. Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy. Blood 2002, 99:2179-2184.
10. De Jonge H.J., Valk P.J., Veeger N.J., ter Elst A., den Boer M.L., Cloos J., et al. High VEGFC expression is associated with unique gene expression profiles and predicts adverse prognosis in pediatric and adult acute myeloid leukemia. Blood 2010, 116:1747-1754.
11. Hooper A.T., Butler J.M., Nolan D.J., Kranz A., Iida K., Kobayashi M., et al. Engraftment and reconstitution of hematopoiesis is dependent onVEGFR2-mediated regeneration of sinusoidal endothelial cells. Cell Stem Cell 2009, 4:263-274.
12. Lee J.Y., Park S., Kim D.C., Yoon J.H., Shin S.H., Min W.S., et al. A VEGFR-3 antagonist increases IFN-gamma expression on low functioning NK cells in acute myeloid leukemia. J. Clin. Immunol 2013, 33:826-837.
13. Sciume G., De Angelis G., Benigni G., Ponzetta A., Morrone S., Santoni A., et al. CX3CR1 expression defines 2 KLRG1+ mouse NK-cell subsets with distinct functional properties and positioning in the bone marrow. Blood 2011, 117:4467-4475.
14. Kirkin V., Thiele W., Baumann P., Mazitschek R., Rohde K., Fellbrich G., et al. MAZ51, an indolinone that inhibits endothelial cell and tumor cell growth in vitro, suppresses tumor growth in vivo. Int. J. Cancer 2004, 112:986-993.
15. Kirkin V., Mazitschek R., Krishnan J., Steffen A., Waltenberger J., Pepper M.S., et al. Characterization of indolinones which preferentially inhibit VEGF-C- and VEGF-D-induced activation of VEGFR-3 rather than VEGFR-2. Eur. J. Biochem 2001, 268:5530-5540.
16. Sorensen E.W., Gerber S.A., Frelinger J.G., Lord E.M. IL-12 suppresses vascular endothelial growth factor receptor 3 expression on tumor vessels by two distinct IFN gamma-dependent mechanisms. J. Immunol 2010, 184:1858-1866.
17. Cheon D.J., Orsulic S. Mouse models of cancer. Annu. Rev. Pathol 2011, 6:95-119.
18. Daser A., Rabbitts T.H. Extending the repertoire of the mixed-lineage leukemia gene MLL in leukemogenesis. Genes Dev 2004, 18:965-974.
19. Kim H., Cho H.J., Kim S.W., Liu B., Choi Y.J., Lee J., et al. CD31+ cells represent highly angiogenic and vasculogenic cells in bone marrow: novel role of nonendothelial CD31+ cells in neovascularization and their therapeutic effects on ischemic vascular disease. Cir. Res 2010, 107:602-614.
20. Perez-Atayde A.R., Sallan S.E., Tedrow U., Connors S., Allred E., Folkman J. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am. J. Pathol 1997, 150:815-821.
21. Hussong J.W., Rodgers G.M., Shami P.J. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood 2000, 95:309-313.
22. Fujisaki H., Kakuda H., Shimasaki N., Imai C., Ma J., Lockey T., et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res 2009, 69:4010-4017.
23. Schliemann C., Roesli C., Kamada H., Borgia B., Fugmann T., Klapper W., et al. In vivo biotinylation of the vasculature in B-cell lymphoma identifies BST-2 as a target for antibody based therapy. Blood 2010, 115:736-744.
24. Passineau M.J., Siegal G.P., Everts M., Pereboev A., Jhala D., Wang M., et al. The natural history of a novel, systemic, disseminated model of syngeneic mouse B-cell lymphoma. Leuk. Lymphoma 2005, 46:1627-1638.
25. Di Santo J.P. Natural killer cell developmental pathways: a question of balance. Annu. Rev. Immunol 2006, 24:257-286.
26. Vivier E., Tomasello E., Baratin M., Walzer T., Ugolini S. Functions of natural killer cells. Nat. Immunol 2008, 9:503-510.
27. Gunji Y., Vujanovic N.L., Hiserodt J.C., Herberman R.B., Gorelik E. Generation and characterization of purified adherent lymphokine-activated killer cells in mice. J. Immunol 1989, 142:1748-1754.
28. Kim S., Iizuka K., Kang H.S., Dokun A., French A.R., Greco S., et al. In vivo developmental stages in murine natural killer cell maturation. Nat. Immunol 2002, 3:523-528.
29. Kataru R.P., Kim H., Jang C., Choi D.K., Koh B.I., Kim M., et al. T lymphocytes negatively regulate lymph node lymphatic vessel formation. Immunity 2011, 34:96-107.
30. Fathallah-Shaykh H.M., Zhao L.J., Kafrouni A.I., Smith G.M., Forman J. Gene transfer of IFN-gamma into established brain tumors represses growth by antiangiogenesis. J. Immunol 2000, 164:217-222.
31. Ibe S., Qin Z., Schuler T., Preiss S., Blankenstein T. Tumor rejection by disturbing tumor stroma cell interactions. J. Exp. Med 2001, 194:1549-1559.
32. Shao X., Liu C. Influence of IFN- alpha and IFN- gamma on lymphangiogenesis. J. Interferon Cytokine Res 2006, 26:568-574.
33. Kalkunte S.S., Mselle T.F., Norris W.E., Wira C.R., Sentman C.L., Sharma S. Vascular endothelial growth factor C facilitates immune tolerance and endovascular activity of human uterine NK cells at the maternal-fetal interface. J. Immunol 2009, 182:4085-4092.
34. Nowbakht P., Ionescu M.C., Rohner A., Kalberer C.P., Rossy E., Mori L., et al. Ligands for natural killer cell-activating receptors are expressed upon the maturation of normal myelomonocytic cells but at low levels in acute myeloid leukemias. Blood 2005, 105:3615-3622.
35. Zamai L., Ahmad M., Bennett I.M., Azzoni L., Alnemri E.S., Perussia B. Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J. Exp. Med 1998, 188:2375-2380.
36. Fruci D., Lo Monaco E., Cifaldi L., Locatelli F., Tremante E., Benevolo M., et al. T and NK cells: two sides of tumor immunoevasion. J. Transl. Med 2013, 11:30.
37. Brincks E.L., Katewa A., Kucaba T.A., Griffith T.S., Legge K.L. CD8 T cells utilize TRAIL to control influenza virus infection. J. Immunol 2008, 181:4918-4925.
38. Wang Y., Nakayama M., Pitulescu M.E., Schmidt T.S., Bochenek M.L., Sakakibara A., et al. Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis. Nature 2010, 465:483-486.